AVEO Oncology recognized colleagues at AVEO Oncology on Labor Day to advance treatment options for patients.

Public source

Publisher name

Public post

This #LaborDay, we recognize the dedication and hard work of people around the country, including our colleagues at AVEO Oncology, an LG Chem company, who remain committ…

Log in to read the full post

Company

AVEO Oncology

Committed to delivering medicines that provide a better life for patients with cancer.

Industry
Biotechnology Research
Location
Boston, US
Company size
201–500 employees

About AVEO Oncology

AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.

See more

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.